Pulmonary arterial hypertension in connective tissue diseases

Paul M Hassoun, Britta Maurer, Oliver Distler

Research output: Contribution to journalArticle

Abstract

Pulmonary arterial hypertension (PAH) is a common complication of connective tissue diseases (CTD) and a leading cause of death in this population. Despite significant advances in therapy for PAH, particularly for idiopathic PAH (IPAH), the response to treatment in patients with CTD associated with PAH, mainly in sclerodermaassociated PAH (SSc-PAH), has been quite disappointing. This chapter reviews the epidemiology, clinical manifestations, pathophysiology and currently available therapies for CTDassociated PAH with a particular focus on SSc-PAH, animal models of disease, and newly identified potential targets for therapy for this devastating syndrome.

Original languageEnglish (US)
Pages (from-to)42-57
Number of pages16
JournalEuropean Respiratory Monograph
Volume57
DOIs
StatePublished - 2012

Fingerprint

Connective Tissue Diseases
Pulmonary Hypertension
Animal Disease Models
Therapeutics
Cause of Death
Epidemiology
Population

Keywords

  • Connective tissue disease
  • Pulmonary arterial hypertension
  • Systemic sclerosis
  • Therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pulmonary arterial hypertension in connective tissue diseases. / Hassoun, Paul M; Maurer, Britta; Distler, Oliver.

In: European Respiratory Monograph, Vol. 57, 2012, p. 42-57.

Research output: Contribution to journalArticle

Hassoun, Paul M ; Maurer, Britta ; Distler, Oliver. / Pulmonary arterial hypertension in connective tissue diseases. In: European Respiratory Monograph. 2012 ; Vol. 57. pp. 42-57.
@article{f0508a853f8748c183d474a879c42836,
title = "Pulmonary arterial hypertension in connective tissue diseases",
abstract = "Pulmonary arterial hypertension (PAH) is a common complication of connective tissue diseases (CTD) and a leading cause of death in this population. Despite significant advances in therapy for PAH, particularly for idiopathic PAH (IPAH), the response to treatment in patients with CTD associated with PAH, mainly in sclerodermaassociated PAH (SSc-PAH), has been quite disappointing. This chapter reviews the epidemiology, clinical manifestations, pathophysiology and currently available therapies for CTDassociated PAH with a particular focus on SSc-PAH, animal models of disease, and newly identified potential targets for therapy for this devastating syndrome.",
keywords = "Connective tissue disease, Pulmonary arterial hypertension, Systemic sclerosis, Therapy",
author = "Hassoun, {Paul M} and Britta Maurer and Oliver Distler",
year = "2012",
doi = "10.1183/1025448x.10018711",
language = "English (US)",
volume = "57",
pages = "42--57",
journal = "European Respiratory Monograph",
issn = "1025-448X",
publisher = "European Respiratory Society",

}

TY - JOUR

T1 - Pulmonary arterial hypertension in connective tissue diseases

AU - Hassoun, Paul M

AU - Maurer, Britta

AU - Distler, Oliver

PY - 2012

Y1 - 2012

N2 - Pulmonary arterial hypertension (PAH) is a common complication of connective tissue diseases (CTD) and a leading cause of death in this population. Despite significant advances in therapy for PAH, particularly for idiopathic PAH (IPAH), the response to treatment in patients with CTD associated with PAH, mainly in sclerodermaassociated PAH (SSc-PAH), has been quite disappointing. This chapter reviews the epidemiology, clinical manifestations, pathophysiology and currently available therapies for CTDassociated PAH with a particular focus on SSc-PAH, animal models of disease, and newly identified potential targets for therapy for this devastating syndrome.

AB - Pulmonary arterial hypertension (PAH) is a common complication of connective tissue diseases (CTD) and a leading cause of death in this population. Despite significant advances in therapy for PAH, particularly for idiopathic PAH (IPAH), the response to treatment in patients with CTD associated with PAH, mainly in sclerodermaassociated PAH (SSc-PAH), has been quite disappointing. This chapter reviews the epidemiology, clinical manifestations, pathophysiology and currently available therapies for CTDassociated PAH with a particular focus on SSc-PAH, animal models of disease, and newly identified potential targets for therapy for this devastating syndrome.

KW - Connective tissue disease

KW - Pulmonary arterial hypertension

KW - Systemic sclerosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84865608467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865608467&partnerID=8YFLogxK

U2 - 10.1183/1025448x.10018711

DO - 10.1183/1025448x.10018711

M3 - Article

AN - SCOPUS:84865608467

VL - 57

SP - 42

EP - 57

JO - European Respiratory Monograph

JF - European Respiratory Monograph

SN - 1025-448X

ER -